What is Cyprotex?
Cyprotex operates as a specialized research organization dedicated to the rigorous evaluation of pharmaceutical candidates. By focusing on absorption, distribution, metabolism, and pharmacokinetic properties, the firm provides the foundational data necessary for pharmaceutical and biotechnology companies to navigate the complexities of early-stage development. Their technical expertise serves as a critical bridge between initial discovery and clinical trials, effectively mitigating risk for developers. By providing reliable, data-driven assessments, Cyprotex enables its clients to optimize their development pipelines and allocate resources toward the most promising therapeutic candidates. The company's market position is defined by its ability to deliver precise, actionable insights that inform high-stakes decision-making in the life sciences sector.
How much funding has Cyprotex raised?
Cyprotex has raised a total of $10.8M across 1 funding round:
Debt
$10.8M
Debt (2013): $10.8M with participation from Harwood Capital
Key Investors in Cyprotex
Harwood Capital
Harwood Capital Management Group is an investment management firm overseeing significant assets across public and private equities, with a focus on active engagement in the management of its portfolio companies.
What's next for Cyprotex?
With the support of this major strategic investment, Cyprotex is well-positioned to scale its analytical infrastructure and expand its service offerings. The company is expected to leverage this capital to enhance its laboratory methodologies and deepen its integration within the global pharmaceutical supply chain. As the industry continues to prioritize efficiency and risk reduction in drug discovery, Cyprotex's role as a specialized service provider becomes increasingly vital. Future growth will likely focus on technological advancements in predictive modeling and the expansion of its client base among contract research organizations and emerging biotech firms, ensuring the company remains at the forefront of preclinical innovation.
See full Cyprotex company page
